What question did this study set out to answer?

To determine whether combining the EGFR-targeted antibody panitumumab with irinotecan improves overall survival compared with irinotecan alone in patients with pretreated, KRAS wild-type advanced colorectal cancer.

May 28, 2013The Lancet OncologyOpen Access

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

View Full Paper

Ask AI

Bookmark

To determine whether combining the EGFR-targeted antibody panitumumab with irinotecan improves overall survival compared with irinotecan alone in patients with pretreated, KRAS wild-type advanced colorectal cancer.
Open-label, prospectively stratified randomized trial conducted across 60 centers in the UK (ISRCTN93248876) enrolling patients with advanced colorectal cancer progressing after fluoropyrimidine therapy.
The primary analysis cohort included 460 patients with KRAS codons 12, 13, and 61 wild-type tumors and no prior EGFR therapy, randomly allocated 1:1 to irinotecan alone (350 mg/m² IV every 3 weeks) or irinotecan plus panitumumab (9 mg/kg IV every 3 weeks).
Tumor DNA underwent pyrosequencing for KRAS codon 146, BRAF, NRAS, and PIK3CA mutations to evaluate predefined molecular subgroups.
No significant difference was observed in the primary endpoint of overall survival between the irinotecan plus panitumumab and irinotecan groups (HR 1.01, 95% CI 0.83–1.23; p=0.91).
Panitumumab significantly improved progression-free survival (HR 0.78, 95% CI 0.64–0.95; p=0.015) and objective response rate (34% [79/230] vs 12% [27/230]; p<0.0001).
Grade 3 or worse toxicities were higher with combination therapy, including diarrhea (29% vs 18%), skin toxicity (19% vs 0%), lethargy (21% vs 11%), infection (19% vs 10%), and hematological toxicity (22% vs 12%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates no overall survival benefit from adding panitumumab to irinotecan in KRAS wild-type colorectal cancer, indicating the need for refined molecular selection.

Cite This Study

Seymour et al. (2013) studied this question.

synapsesocial.com/papers/6a1b65e40ea968f653abce0c https://doi.org/10.1016/s1470-2045(13)70163-3

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates no overall survival benefit from adding panitumumab to irinotecan in KRAS wild-type colorectal cancer, indicating the need for refined molecular selection.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Key Points

Discussion

Implication

Cite This Study

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider